MIR9-3

Summary

MIR9-3 (microRNA 9-3, HGNC:31646) is a microRNA gene on chromosome 15q26.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407051 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31646
Approved symbol	MIR9-3
Name	microRNA 9-3
Location	15q26.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-9-3
Ensembl gene	ENSG00000284329
Ensembl biotype	miRNA
OMIM	611188
Entrez	407051
RNAcentral	URS00005D97FE — miRNA, 90 nt, 2 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385084

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385084 — 1 exons

Exon	Start	End
ENSE00001500090	89368017	89368106

Expression profiles

Bgee: expression breadth broad, 17 present calls, max score 95.10.

Top tissues by expression

17 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	95.10	gold quality
monocyte	CL:0000576	74.24	gold quality
ascending aorta	UBERON:0001496	70.34	gold quality
putamen	UBERON:0001874	69.00	gold quality
right hemisphere of cerebellum	UBERON:0014890	67.06	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	65.55	gold quality
amygdala	UBERON:0001876	65.47	gold quality
minor salivary gland	UBERON:0001830	65.35	gold quality
right frontal lobe	UBERON:0002810	64.78	gold quality
caudate nucleus	UBERON:0001873	63.93	gold quality
anterior cingulate cortex	UBERON:0009835	62.09	gold quality
nucleus accumbens	UBERON:0001882	60.41	gold quality
Ammon’s horn	UBERON:0001954	60.41	gold quality
cerebellar hemisphere	UBERON:0002245	59.36	gold quality
pituitary gland	UBERON:0000007	57.07	gold quality
right testis	UBERON:0004534	44.38	gold quality
left testis	UBERON:0004533	43.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RUNX1

Literature-anchored findings (GeneRIF, showing 40)

• both miR-9-1 and miR-9-3 are significantly hypermethylated in clear cell renal cell carcinoma (PMID:20676129)
• Transgenic mice lacking miR-9-2 and miR-9-3 exhibit multiple defects of telencephalic structures which may be brought about by dysregulation of Foxg1, Nr2e1, Gsh2, and Meis2 expression. (PMID:21368052)
• Findings suggest that bile miRNAs could be informative biomarkers for hepatobiliary disease and that some miRNAs, particularly miR-9, may be helpful in the diagnosis and clinical management of BTC. (PMID:21858175)
• The methylation of mir-9-3, mir-124-2, and mir-124-3 was individually associated with an advanced T factor independent of age, sex, and smoking habit. (PMID:21917081)
• Three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. (PMID:21931274)
• miR-9-3 and miR-193a were found to be tumor specifically methylated in patients with NSCLC. (PMID:22282464)
• Data indicate that methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis. (PMID:22703336)
• Results indicate that upregulated miR-20b, miR-9, and miR-9* were significantly associated with HPV/p16-status. (PMID:23459718)
• Overexpression of MIR9 indicates poor prognosis in acute lymphoblastic leukemia. (PMID:23547834)
• The CXC chemokine receptor 4 (CXCR4) gene was a direct target of miR-9. (PMID:24141785)
• Demethylation of miR-9-3 gene may produce proliferation-inhibiting and apoptosis-promoting effects due to repression of NF-kappaB and MCL1. (PMID:24356455)
• results revealed that miR-9-3 was a tumor suppressor miRNA hypermethylated in chronic lymphocytic leukemia, which was associated with down-regulation of NFKB1 protein. (PMID:24373626)
• This study provides further data for the identification of a miRNA profile for glioblastoma and suggests that different-grade neoplasia could be characterized by different expression of specific miRNAs. (PMID:24412053)
• MicroRNA-9 has a role in promoting tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma (PMID:25375090)
• Data indicate the potential of miR-9 as a novel prognostic biomarker for hepatocellular carcinoma. (PMID:25552204)
• Data reveal a novel role for miR-9 in regulation of the NFAT pathway by targeting KPNB1 and DYRK1B. (PMID:25696812)
• The promoters of miR-9 precursors (mir-9-1, -2, and -3) were hypermethylated in cervical adenocarcinoma tissues; results present a tumor suppressor potential of miR-9 in cervical adenocarcinoma and suggest that miR-9 could repress tumorigenesis through inhibiting the activity of IL-6/Jak/STAT3 pathway. (PMID:25809226)
• Reversible hypermethylation of miR-9-3 and miR-9-1 occurs frequently in multiple myeloma cell lines but not in primary samples. (PMID:25855800)
• miR-9 could repress the expression of UHRF1, and function as a tumor-suppressive microRNA in colorectal cancer. (PMID:25940709)
• miRNA 9 is a potential marker for the prognosis and follow up of patients with type 2 diabetes at risk to develop coronary artery disease. (PMID:25978320)
• MicroRNA-9-3p was identified as the tumour-suppressor miR targetting TAZ expression in hepatocellular carcinoma cells. (PMID:26125451)
• Methylation-associated miR-9 down-regulation is probably one of the key mechanisms for paclitaxel resistance in EOC cells, via targeting CCNG1. (PMID:26152689)
• miR9 methylation, especially miR9-2, is a frequent event in Hodgkin lymphoma (HL) and may be involved in HL pathogenesis, irrespective of EBV infection (PMID:26337487)
• Inhibition of miRNA93p reduced the proliferation of HepG2 cells and lipid accumulation by upregulating the expression of SIRT1. (PMID:26459099)
• miR-9 might play a tumor suppressive role in oral squamous cell carcinoma and can serve as a promising biomarker for this deadly disease. (PMID:26813876)
• Findings indicate the importance of a microRNAs miR-9/137-CUL4A-Hippo signaling axis in gastric cancer (GC), and suggest new therapeutic targets for future treatment of GC. (PMID:26840256)
• Down-regulation of miR-9 in human diabetic failing heart.MiR-9 directly targets ELAVL1 in ventricular cardiomyocytes. (PMID:26898797)
• Results suggest that miR-9 functions as a tumor-suppressor in colorectal cancer cells, and that its suppressive effects mediate invasion and metastasis by inhibition of TM4SF1 expression. (PMID:26983891)
• miRNA-145 and 9 may be potential prognostic marker in patients suffering from cervical cancer. (PMID:27345415)
• The results of this study demonstrated that miR-9-3p is critically involved in hippocampal LTP and long-term memory. (PMID:27535911)
• We concluded that smoking habits were capable of inducing changes in global DNA methylation, miR-9-3 methylation status and K19 expression. (PMID:27543926)
• miR-9 expression was negatively associated with PTEN expression in laryngocarcinoma cells, modulating cell proliferation and metastasis. (PMID:27694005)
• Data suggest that miR-124-3p, miR-9-3p and miR-196b-5p may be potential signatures for differential diagnosis of thyroid nodules in eastern coastal areas of China. (PMID:27705935)
• These results shed additional information on controversial expression pattern of miR-9 depending on different progression level of breast cancer. (PMID:27725294)
• Results show that interleukin-10 (IL-10) positively regulated the expression of E-cadherin by downregulation of microRNA miR-9 in leukemia cells. (PMID:28107581)
• Study showed that miR-9 was downregulated in adriamycinresistant K562/ADR cells and chronic myelogenous leukemia (CML)/MDR patients. Overexpression of miR-9 was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro. Furthermore, ABCB1 was found as a direct target of miR-9. These findings suggest that miR-9 plays a critical role in MDR in CML by targeting ABCB1. (PMID:28260112)
• Our study provides evidence that miR-9 can promote the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1. (PMID:28397066)
• results indicated that low expression of miR-9-3p results in a high level of Herpud1, which may protect against apoptosis in glioma (PMID:28430789)
• Elevation of miR-9-3p suppresses the proliferation and metastases of nasopharyngeal carcinoma via downregulating FN1, ITGB1, ITGAV and inhibiting the epithelial-mesenchymal transition process. (PMID:28613134)
• Results show that serum levels of miR-9, PEDF and VEGF are increased with diabetic nephropathy (DN) progression. miR-9, VEGF and PEDF are independent risk factors of DN. Serum miR-9 level is positively related to the levels of VEGF, PEDF and biochemical indices. (PMID:28667418)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir9-3	ENSMUSG00000093238

Paralogs (2): MIR9-1 (ENSG00000207933), MIR9-2 (ENSG00000284447)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.